AstraZeneca plans to file for regulatory approval of its experimental blood pressure treatment before the end of the year, a ...

Doctors may soon have a new way to treat high blood pressure, even among people for whom medicines haven’t worked well in the ...

Adults with undiagnosed asthma or chronic obstructive pulmonary disease exhibit severe cough, which is associated with poorer ...

AstraZeneca (AZN) stock in focus as the company plans regulatory filings for its blood pressure drug baxdrostat by year's end, aiming for 2026 approval. Read more here.

Less than a year after a scandal embroiled its then China boss, pharma group AstraZeneca appears to have bounced back, ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

Study results show mortality benefit from low-dose digitoxin for heart failure in symptomatic patients with reduced ejection fraction.

A new once-a-day pill that lowers blood pressure 'spectacularly' could help millions in the UK whose levels remain high ...

Virginia lawmakers have approved two proposed economic development packages for advanced pharmaceutical manufacturing plants ...

Adding baxdrostat to background antihypertensive therapy led to substantial reductions in seated systolic blood pressure after 12 weeks of treatment among patients with uncontrolled or resistant ...

The University of Michigan has sued pharmaceutical giant AstraZeneca, alleging the company is still using the university's intellectual property in FluMist two years after the licensing agreement ...

About four in 10 patients taking the drug reached a healthy blood pressure level – which is typically considered under 130mmHg – compared with fewer than two in 10 taking a placebo, having previously ...